Checkpoint Therapeuticsの空売り状況は、投資家がCheckpoint Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Checkpoint Therapeutics (NASDAQ:CKPT) 株価情報, 空売り情報

CHECKPOINT THERAPEUTICS INC

Checkpoint Therapeutics

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Checkpoint Therapeutics, Inc. - Common Stock

Checkpoint Therapeutics Inc

B. Riley Securities analyst Josh Nichols maintains Nayax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) with a Buy and raises the price target from $44 to $47.

News

Price Target

Analyst Ratings

NYAX

B. Riley Securities Maintains Buy on Nayax, Raises Price Target to $47

B. Riley Securities analyst Josh Nichols maintains 8x8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) with a Buy and lowers the price target from $4 to $3.

EGHT

B. Riley Securities Maintains Buy on 8x8, Lowers Price Target to $3

B. Riley Securities analyst David Bain maintains DoubleDown Interactive Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDI#NASDAQ">DDI</a>) with a Buy and lowers the price target from $23 to $22.

B. Riley Securities Maintains Buy on DoubleDown Interactive Co, Lowers Price Target to $22

CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) has outperformed the market over the past 10 years by 8.23% on an annualized basis producing an average annual return of 18.92%. Currently, CyberArk Software has a market capitalization of $17.62 billion. 
Buying $1000 In CYBR: If an investor had bought $1000 of CYBR stock 10 years ago, it would be worth $5,650.80 today based on a price of $357.54 for CYBR at the time of writing.
<h3>CyberArk Software's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747239479_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

CYBR

Here's How Much You Would Have Made Owning CyberArk Software Stock In The Last 10 Years

B. Riley Securities analyst Craig Ellis maintains Camtek (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>) with a Buy and raises the price target from $85 to $95.

CAMT

B. Riley Securities Maintains Buy on Camtek, Raises Price Target to $95

Shares of Aurora Innovation Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) are trading lower by 8.81% to $6.67 during Wednesday&#8217;s session after Uber Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) announced plans to monetize part of its stake in the autonomous vehicle company through a $1 billion <a href="https://www.benzinga.com/news/offerings/25/05/45393539/aurora-innovation-stock-drops-after-the-bell-whats-going-on">convertible note offering</a>.
What To Know: According to an <a href="https://www.benzinga.com/pressreleases/25/05/b45397128/uber-announces-pricing-of-1-0-billion-exchangeable-senior-notes-offering">SEC filing</a>, Uber will privately place senior notes due 2028 with institutional investors. The zero-coupon notes will be exchangeable for Aurora common stock at an initial exchange price of approximately $8.50 per share. The offering includes an option for an additional $150 million in notes and is expected to close on May 20.
Uber <a href="https://www.benzinga.com/news/offerings/25/05/45393539/aurora-innovation-stock-drops-after-the-bell-whats-going-on">acquired</a> its Aurora stake in 2020 when it sold its self-driving unit to the company in an all-equity deal worth $400 million, securing a 26% ownership. CEO Dara Khosrowshahi, who joined Aurora's board as part of the deal, plans to step down by year-end.
The notes will be secured by Uber's Aurora shares through its subsidiary Neben Holdings. Uber expects to use the net proceeds, anticipated at around $979 million, for general corporate purposes, potentially including strategic investments.
Read Also: <a href="https://www.benzinga.com/news/25/05/45408806/zevra-therapeutics-zvra-stock-jumps-on-strong-q1-results-whats-going-on">Zevra Therapeutics Stock Jumps on Strong Q1 Results: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy AUR Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Aurora Innovation&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AUR has a 52-week high of $10.77 and a 52-week low of $2.10.
Photo: courtesy of Aurora Innovation.

Movers

UBER

Aurora Innovation Shares Fall As Uber Announces $1B Note Offering: What's Going On?

Truist Securities analyst Nicole Germino maintains Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) with a Buy and lowers the price target from $18 to $14.

YMAB

Truist Securities Maintains Buy on Y-mAbs Therapeutics, Lowers Price Target to $14

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Wednesday.
The Dow traded up 0.08% to 42,172.43 while the NASDAQ gained 0.74% to 19,151.42. The S&amp;P 500 also rose, gaining, 0.24% to 5,900.93.
Check This Out: <a href="https://www.benzinga.com/25/05/45402795/top-3-materials-stocks-that-could-blast-off-this-month">Top 3 Materials Stocks That Could Blast Off This Month</a>
Leading and Lagging Sectors Communication services shares jumped by 1.6% on Wednesday.
In trading on Wednesday, health care stocks fell by 1.4%.
Top Headline
U.S. crude oil inventories increased by 3.454 million barrels in the week ended May 9, compared to market estimates of a 1 million barrel decline.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) shares shot up 672% to $0.6586 after the company completed patient dosing in the Phase 2 portion of its Phase 2/3 RePOSA study of IHL-42X for obstructive sleep apnea.</li>
<li>Shares of Septerna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) got a boost, surging 44% to $9.71 after the company announced an exclusive global collaboration and license agreement with Novo Nordisk to develop oral small molecule medicines for obesity, type 2 diabetes, and other cardiometabolic diseases.</li>
<li>Nutex Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares were also up, gaining 25% to $157.12 after the company reported better-than-expected first-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Global-E Online Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) shares dropped 15% to $36.12 following first-quarter results.</li>
<li>Shares of Cellebrite DI Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NASDAQ">CLBT</a>) were down 11% to $17.82 after the company reported mixed first-quarter financial results and cut its FY25 sales guidance with its midpoint below estimates. Also, the company issued second-quarter sales guidance with its midpoint below estimates.</li>
<li>Loar Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOAR#NYSE">LOAR</a>) was down, falling 8% to $86.20 after the company launched a secondary public offering consisting of 9 million shares.</li>
</ul>
Commodities In commodity news, oil traded down 0.5% to $63.33 while gold traded down 1.9% at $3,186.40.
Silver traded down 2% to $32.440 on Wednesday, while copper fell 1.4% to $4.6550.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.24%, while Spain's IBEX 35 Index rose 0.52%. London's FTSE 100 slipped 0.21%, Germany's DAX 40 fell 0.47% and France's CAC 40 slipped 0.47% during the session.
Asia Pacific Markets
Asian markets closed mostly higher on Wednesday, with Japan's Nikkei falling 0.14%, Hong Kong's Hang Seng Index gaining 2.30%, China's Shanghai Composite Index gaining 0.86% and India's BSE Sensex gaining 0.22%.
Economics
<ul class="wp-block-list">
<li>U.S. mortgage application volumes increased by 1.1% from the previous week in the week ending May 9, following an 11% surge in the prior period.</li>
<li>U.S. crude oil inventories increased by 3.454 million barrels in the week ended May 9, compared to market estimates of a 1 million barrel decline.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

CLBT

GLBE

IXHL

LOAR

NUTX

SEPN

Dow Edges Higher; US Crude Oil Inventories Increase

Truist Securities analyst Joseph Civello maintains Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) with a Hold and lowers the price target from $9 to $7.

Truist Securities Maintains Hold on Under Armour, Lowers Price Target to $7

Truist Securities analyst Nicole Germino maintains Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) with a Buy and lowers the price target from $10 to $8.

CATX

Truist Securities Maintains Buy on Perspective Therapeutics, Lowers Price Target to $8

Rumors

IPOs

ETOR

Etoro Group IPO Price Indicating $69.50 On 1.2M Shares; IPO Priced At $52/Share On 11,923,018 Shares

Truist Securities analyst Mark Hughes maintains PennantPark Floating Rate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFLT#NYSE">PFLT</a>) with a Buy and lowers the price target from $12 to $11.

PFLT

Truist Securities Maintains Buy on PennantPark Floating Rate, Lowers Price Target to $11

This week's cannabis earnings highlighted a widening divergence between U.S. operators. LEEF Brands (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/LEEEF#OTCQB">LEEEF</a>) saw its stock jump nearly 25% after striking a new dispensary management and supply deal with Glass House Brands (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/GLASF#OTCQX">GLASF</a>). Meanwhile, Glass House rose 4.5% on solid Q1 results, Charlotte's Web (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTCQX">CWBHF</a>) traded flat despite its first year-over-year revenue growth in years and AFC Gamma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFCG#NASDAQ">AFCG</a>) dipped almost 2% as it worked to de-risk its lending book.
Here's a breakdown of each company's report and what investors need to know.
<h3 class="wp-block-heading">LEEF Brands</h3>
Shares of LEEF Brands surged nearly 25% Wednesday after announcing a new management services agreement with Glass House Brands to operate The LEAF El Paseo, a Palm Desert dispensary. The deal gives Glass House control over daily operations, while LEEF secures a significant biomass supply agreement to fuel its extraction lines.
"This partnership is a true win-win," said LEEF CEO Micah Anderson. "It allows us to sharpen our focus on concentrates while strengthening production capacity."
The agreement marks Glass House's first formal retail management deal and offers both companies strategic upside. For Glass House, it expands retail reach without the capital requirements of building new stores. For LEEF, it enhances supply chain security while offloading operational complexity in retail.
<h3 class="wp-block-heading">Glass House Brands</h3>
Glass House Brands reported first-quarter 2025 revenue of $44.8 million, up 49% year-over-year. Wholesale biomass revenue grew 78%, driven by a 149% increase in production volume and a 41% drop in cost per pound, which now sits at $108. Retail revenue also rose 19%, outperforming a California market that shrank 13% during the same period, according to Headset data.
Gross margin reached 45%, and adjusted EBITDA came in at $4.4 million—above guidance. While net income remained negative at -$10 million, the company posted a positive operating cash flow of $2.5 million and ended the quarter with $37.6 million in cash and equivalents.
CEO Kyle Kazan credited the results to Glass House's status as a low-cost, high-quality producer. "Even with ongoing pricing pressures in California, we're positioned to emerge stronger as the market consolidates," he said.
The company also reaffirmed its full-year guidance of $220–230 million in revenue and mid-$40 million in adjusted EBITDA while preparing for added production from Greenhouse 2 and expansion into compliant hemp operations.
<h3 class="wp-block-heading">Charlotte's Web</h3>
Charlotte's Web posted its first year-over-year revenue increase since 2021, with Q1 2025 sales of $12.3 million, up 1.1% compared to the same period last year. The modest gain builds on a streak of sequential growth throughout 2024 and is attributed to improvements in e-commerce performance, digital expansion on platforms like Amazon and TikTok Shop, and the upcoming retail rollout at Whole Foods Market.
Gross margin for the quarter was 50.8%, while the company narrowed its net loss to $6.2 million from $9.7 million in Q1 2024. Adjusted EBITDA improved to -$2.8 million from -$3.9 million year-over-year.
The company is also expanding beyond CBD into functional mushroom products and recently announced FDA clearance for a Phase 2 clinical trial of its botanical drug candidate AJA001, developed through its DeFloria joint venture with Ajna BioSciences and backed by British American Tobacco. Charlotte's Web will highlight the project during a panel session at the upcoming Benzinga <a href="https://www.benzinga.com/cannabis-conference">Cannabis Capital Conference in Chicago</a>.
Despite flat movement in CWBHF shares post-earnings, management remains confident. CFO Erika Lind said the company's cost restructuring and in-house manufacturing shift "support near-term cash flow and long-term innovation investment."
<h3 class="wp-block-heading">Advanced Flower Capital (AFC Gamma)</h3>
Cannabis REIT Advanced Flower Capital reported GAAP net income of $4.1 million in Q1 2025, or $0.18 per share. Distributable earnings—a non-GAAP metric—came in at $4.5 million, or $0.21 per share.
CEO Dan Neville emphasized the firm's focus on reducing exposure to distressed borrowers while selectively deploying capital to stronger operators. "We're positioning AFC to capitalize on market dislocations while maintaining credit discipline," he said.
The company paid a quarterly dividend of $0.23 per share, but AFCG shares fell nearly 2% after the results, reflecting cautious investor sentiment in the cannabis lending space.
Earnings included a reversal of $699,000 in loan loss provisions, offset by nearly $700,000 in unrealized non-cash losses. Weighted average share count for the quarter was just over 22 million.
Photo: Shutterstock

Cannabis

Events

AFCG

CWBHF

GLASF

LEEEF

Why LEEF Brands' Stock Is Up 25% Today And A Look At Cannabis Earnings: Glass House, Charlotte's Web, AFC Gamma

Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) shares <a href="https://www.benzinga.com/movers">edged higher on Wednesday</a> after the company revealed a major retail collaboration with Costco Wholesale Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>).
The financial technology firm has entered a long-term agreement to provide its &#8220;pay-over-time&#8221; services to online Costco <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45405590/costco-and-affirm-partner-to-bring-new-flexible-payment-option-to-costco-com" rel="noreferrer noopener">shoppers across the U.S.</a>
The partnership will enable eligible members to access Affirm&#8217;s monthly installment payment options at checkout for purchases over $500 on Costco.com.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/earnings-beats/25/05/45322588/affirm-holdings-stock-dives-despite-q3-report-of-in-line-revenues-guidance-raise-why-analyst-says-there-is-no-positive-catalyst" rel="noreferrer noopener">Affirm Holdings Stock Dives Despite Q3 Report Of In-Line Revenues, Guidance Raise: Why Analyst Says There Is No Positive Catalyst</a>
Starting immediately, Costco members shopping online can select Affirm during checkout to spread the cost of larger transactions across fixed monthly payments.
Following a brief eligibility check, approved users can finance purchases between $500 and $17,500 using tailored plans that include transparent pricing and no late or hidden fees.
The partnership arrives as U.S. consumers seek alternative financing methods for bigger purchases, especially as summer spending ramps up.
Affirm highlighted that product categories like outdoor furniture, grills, appliances, and storage solutions are seeing seasonal demand spikes, making the timing of this offering particularly relevant.
According to Affirm&#8217;s SVP of Revenue, Pat Suh, the collaboration reflects both companies&#8217; commitment to value-driven consumer solutions. &#8220;Costco members, in particular, know the value of planning ahead and buying in bulk,&#8221; said Suh.
Costco generated roughly $250 billion in sales for the fiscal year ending September 2024, driven by consumer demand for daily essentials and high-ticket items.
Affirm&#8217;s latest move adds to its growing list of retail partnerships as it scales its presence in the competitive pay-over-time financing space.
Price Action: AFRM shares are trading higher by 5.01% to $56.65&nbsp;at last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/buybacks/25/05/45406332/sony-q4-earnings-financial-unit-spin-off-stock-buyback-cautious-outlook-amid-tariffs" target="_blank" rel="noreferrer noopener">Sony Q4 Earnings: Financial Unit Spin-Off, Stock Buyback, Cautious Outlook Amid Tariffs</a></li>
</ul>
Image via Shutterstock

AFRM

COST

Affirm Brings 'Buy Now, Pay Later' To Costco Shoppers

Truist Securities analyst Joseph Civello maintains On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Buy and raises the price target from $61 to $69.

ONON

Truist Securities Maintains Buy on On Holding, Raises Price Target to $69

WIIM

OKLO

Oklo shares are trading higher after the company reported a year-over-year increase in Q1 EPS results.

Truist Securities analyst Mark Hughes maintains MidCap Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFIC#NASDAQ">MFIC</a>) with a Buy and lowers the price target from $16 to $15.

MFIC

Truist Securities Maintains Buy on MidCap Financial, Lowers Price Target to $15

Truist Securities analyst Asthika Goonewardene maintains Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) with a Buy and lowers the price target from $88 to $71.

LEGN

Truist Securities Maintains Buy on Legend Biotech, Lowers Price Target to $71

Truist Securities analyst Michael Swartz maintains Fox Factory Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXF#NASDAQ">FOXF</a>) with a Buy and raises the price target from $28 to $34.

FOXF

Truist Securities Maintains Buy on Fox Factory Holding, Raises Price Target to $34

Truist Securities analyst Jasper Bibb maintains American Public Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) with a Hold and raises the price target from $24 to $30.

APEI

Truist Securities Maintains Hold on American Public Education, Raises Price Target to $30

Press Releases

CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT

Comments

Checkpoint Therapeutics

空売り

Checkpoint Therapeutics (NASDAQ:CKPT) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル